Impact of UGT1A4 Polymorphisms on the Posaconazole Serum Trough Concentrations in Patients with Acute Myeloid Leukemia Receiving Delayed-Release Tablets.
Sign Up to like & getrecommendations! Published in 2025 at "Therapeutic drug monitoring"
DOI: 10.1097/ftd.0000000000001319
Abstract: BACKGROUND Posaconazole (PCZ) is recommended for antifungal prophylaxis in neutropenic patients with acute myeloid leukemia (AML). Although the delayed-release (DR) tablet of PCZ has better bioavailability than the oral suspension, the serum target trough concentrations… read more here.
Keywords: pcz concentrations; acute myeloid; patients acute; ugt1a4 polymorphisms ... See more keywords
Dose Optimisation of Posaconazole and Therapeutic Drug Monitoring in Pediatric Patients
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.833303
Abstract: Experience in the clinical use of posaconazole (PCZ) in pediatric patients is limited, and no specific dose recommendations exist. This study aimed to investigate an appropriate dosing regimen, and assess the exposure-response relationships of PCZ… read more here.
Keywords: dose optimisation; pcz; pcz concentrations; optimisation posaconazole ... See more keywords